Hence, the co-treatment of MET with the antifolate agents (TMP or MTX) on HepG2 cells enhanced the decrease in cancer cell viability through changes in levels of genes involved in the intrinsic pathway of apoptosis; p53, Bax and Bcl-2. The gene discussed is TP53; the disease is cancer.